40258-68-2Relevant academic research and scientific papers
Heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative and preparation method and medical application thereof
-
, (2021/08/14)
The invention relates to a heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative, a preparation method thereof and application of the heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative as a PD-1/PD-L1 inhibitor. Specifically, the invention discloses a compound shown as a formula (I) or a pharmaceutically acceptable salt, a deuterated compound, a stereoisomer, a solvate and a prodrug thereof, and a preparation method and application of the compounds, and the definition of each group in the formula is detailed in the description and claims.
Fused ring derivative inhibitor as well as preparation method and application thereof
-
, (2020/11/25)
The invention relates to a fused ring derivative inhibitor as well as a preparation method and application thereof. Particularly, the invention relates to a compound shown as a general formula (I), apreparation method thereof, a pharmaceutical composition containing the compound and application of the compound serving as an inhibitor in treatment of cancers, infectious diseases and autoimmune diseases, and substituent groups in the general formula (I) are the same as definitions in the specification.
HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
-
, (2019/10/19)
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
-
Page/Page column 35-36, (2010/11/28)
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
